JZYY(SH:600750) Sou Hu Cai Jing·2025-07-30 10:21Core Viewpoint - Jiangzhong Pharmaceutical (600750) has shown a mixed performance in its latest financial results, with a decrease in total revenue but an increase in net profit, indicating potential areas for investment consideration [1][2]. Financial Performance - As of the first quarter of 2025, Jiangzhong Pharmaceutical reported total revenue of 1.184 billion yuan, a year-on-year decrease of 7.03% [1]. - The company's net profit attributable to shareholders was 285 million yuan, reflecting a year-on-year increase of 5.91% [1]. - The company's non-recurring net profit was 261 million yuan, which represents a year-on-year decrease of 1.14% [1]. - Key financial ratios include a current ratio of 1.972, a quick ratio of 1.710, and a debt-to-asset ratio of 28.51% [1]. Market Activity - As of July 30, 2025, Jiangzhong Pharmaceutical's stock closed at 22.28 yuan, with an increase of 1.13% [1]. - The trading volume was 115,400 hands, with a total transaction amount of 257 million yuan [1]. - There was a net outflow of main funds amounting to 10.4685 million yuan, accounting for 4.07% of the transaction amount [1]. Company Background - Jiangzhong Pharmaceutical Co., Ltd. was established in 1996 and is located in Nanchang City, primarily engaged in the pharmaceutical manufacturing industry [2]. - The company has a registered capital of 6,294.44958 million yuan and a paid-in capital of 6,290.17624 million yuan [1]. - The legal representative of the company is Liu Weiquan [1]. Investment and Intellectual Property - Jiangzhong Pharmaceutical has made investments in 19 external enterprises and participated in 5,000 bidding projects [2]. - The company holds 1,189 trademark registrations and 653 patent registrations, along with 152 administrative licenses [2].